Skip to main content
. 2017 Dec 7;24(12):768–778. doi: 10.1038/gt.2017.95

Figure 5.

Figure 5

Evaluation of adeno-associated virus 5 (AAV5) total antibody (TAb) and transduction inhibition (TI) assay selectivity and matrix interference. (a) Ten healthy donors (M1–10). (b) Six lipemic donors (Lip M1–6) and six hemolytic donors (Hem M1–6). All samples were spiked with 9 ng/ml of an anti-AAV5 antibody (gray bars) or left unspiked (white bars) and tested in the anti-AAV5 TAb assay. Horizontal lines: TAb screening cut point of 1.15. (c) Ten healthy donors (M1–10) and 10 donors with hemophilia A (HA M1–10). (d) Nine lipemic donors (Lip M1–9) and nine hemolytic donors (Hem M1–9). All samples were spiked with 180 ng/ml of an anti-AAV5 antibody (gray bars), or left unspiked (white bars) and tested in the AAV5 TI assay. Horizontal lines: TI cut point of 44.9% transduction. All the data (ad) are represented as means±s.d.